Dr. Reddy’s Laboratories announces its intent to appeal court decision in preliminary injunction hearing for Buprenorphine and Naloxone Sublingual Film

HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY,
along with its subsidiaries together referred to as “Dr. Reddy’s”) today
announced its intent to appeal the decision made by the U.S. District
Court for the District of New Jersey in a preliminary injunction hearing
with respect to further sales and commercialization of Dr. Reddy’s
Buprenorphine and Naloxone Sublingual Film within the United States.

The company disagrees with the court’s decision, and will vigorously
appeal it.

Dr. Reddy’s had announced the receipt of the approval, on June 15, 2018
by one of its wholly owned subsidiaries, from the U.S. Food and Drug
Administration (USFDA) for its Buprenorphine and Naloxone Sublingual
Film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, therapeutic
equivalent generic version of Suboxone® (buprenorphine and naloxone)
sublingual film, in the United States market.

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124,
NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company,
committed to providing affordable and innovative medicines for healthier
lives. Through its three businesses – Pharmaceutical Services & Active
Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s
offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars and differentiated
formulations. Our major therapeutic areas of focus are gastrointestinal,
cardiovascular, diabetology, oncology, pain management and dermatology.
Dr. Reddy’s operates in markets across the globe. Our major markets
include – USA, India, Russia & CIS countries, and Europe. For more
information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future
expectations and other forward-looking statements that are based on the
management’s current views and assumptions and involve known or unknown
risks and uncertainties that could cause actual results, performance or
events to differ materially from those expressed or implied in such
statements. In addition to statements which are forward-looking by
reason of context, the words “may”, “will”, “should”, “expects”,
“plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”,
“potential”, or “continue” and similar expressions identify
forward-looking statements. Actual results, performance or events may
differ materially from those in such statements due to without
limitation, (i) general economic conditions such as performance of
financial markets, credit defaults , currency exchange rates , interest
rates , persistency levels and frequency / severity of insured loss
events (ii) mortality and morbidity levels and trends, (iii) changing
levels of competition and general competitive factors, (iv) changes in
laws and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization ,
including related integration issues.

The company assumes no obligation to update any information contained


Dr. Reddy’s Laboratories Ltd.
SAVLA, +91-40-49002135

CALVIN PRINTER, +91-40-49002121